Standard BioTools (LAB) Insider Fenel Eloi Buys 175,923 Shares

Fenel Eloi, an insider at LAB, bought 175,923 shares of the company on June 18, 2026. This transaction is part of a broader trend of insider buying at LAB, as other insiders also acquired shares around the same time.

Insider Buying and Selling at Standard BioTools Inc.

In addition to Fenel Eloi's purchase, several other insiders have been active. On June 20, 2026, Sean MacKay, the Senior Vice President and Chief Business Officer, bought 500,000 shares. On June 18, 2026, Frank Witney, Troy Cox, and Thomas Carey also acquired 99,116, 99,116, and 263,884 shares, respectively. These transactions were not part of any pre-planned trading programs, indicating a direct decision to increase stakes in LAB.

Other Institutional Activity in LAB

Institutional investors are also showing interest in LAB. Casdin Capital holds a significant position with 88,783,856 shares valued at about $81.6 million. Viking Global Investors maintains a stake of 58,651,170 shares worth approximately $53.9 million. MAK Capital One LLC increased its holdings by 6,884,468 shares, reaching 26,172,626 shares, a 35.7% increase. Meanwhile, BlackRock, Inc. slightly reduced its position by 759,849 shares, now holding 24,756,084 shares valued at $22.8 million. Vanguard Capital Management LLC opened a new position with 12,816,070 shares worth about $11.8 million.

Analysts Set New Price Targets

Analysts have set various price targets for LAB. On November 5, 2025, TD Cowen maintained a 'hold' rating with a price target of $1.35. Earlier, TD Cowen initiated coverage on April 16, 2024, with a 'buy' rating and a target of $3.50. Jefferies and KeyBanc also initiated coverage in 2024 and 2023, respectively, both recommending a 'buy' with price targets of $3.25 and $4.00.

Bottom Line

The recent insider buying activity at LAB, including Fenel Eloi's purchase, suggests a positive outlook from those closely associated with the company. While the stock traded near $0.77 on Wednesday, the actions of insiders and institutional investors could indicate confidence in LAB's future prospects. As always, it's important to note that 13F filings and insider reports are backward-looking and may not reflect current holdings.